Navigation Links
Quintessence cancer treatment chosen for clinical studies

Madison, Wis. - Quintessence Biosciences, a biopharmaceutical company developing cancer therapies, has announced that QB139, one of its EVade cancer treatments, has been selected for preclinical testing and human clinical trials.

Quintessence said that pending a favorable preclinical safety assessment, it would submit to the

Source:wistechnology.com By WTN News 11/09/06


Page: 1

Related biology technology :

1. Quintessence Biosciences advances cancer drug
2. Quintessence Biosciences names new president
3. Quintessence division to develop drug tests with NIH grant
4. Quintessence Biosciences forms cancer therapeutic advisory board
5. Quintessence Secures Financing
6. NeoClone gets $750K for ovarian cancer detection
7. Medical College receives $1.4M cancer grant
8. GE Healthcare partners with UNC on breast cancer imaging research
9. Lance Armstrong and the future of cancer care
10. Medical College part of $5M cancer study
11. UW finds new path to anti-cancer agents
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/23/2016)... ... 2016 , ... UAS LifeSciences, one of the leading manufacturers ... Probiotics, into Target stores nationwide. The company, which has been manufacturing high quality ... list of well-respected retailers. This list includes such fine stores as Whole Foods, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software company, ... Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , “I ... President and COO of STACS DNA. “In further expanding our capacity as a scientific ...
(Date:6/23/2016)... NEW YORK , June 23, 2016 ... the trading session at 4,833.32, down 0.22%; the Dow Jones ... the S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ... BIND Therapeutics Inc. (NASDAQ: BIND ). Learn more ...
Breaking Biology Technology:
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. and ... business relationship that includes integrating Syngrafii,s patented LongPen™ ... project. This collaboration will result in greater convenience ... credit union, while maintaining existing document workflow and ... ...
(Date:6/2/2016)... 2016 The Department of Transport Management ... 44 million US Dollar project, for the , ... Personalization, Enrolment, and IT Infrastructure , to ... and implementation of Identity Management Solutions. Numerous renowned international vendors ... Decatur was selected for the most compliant and ...
(Date:6/2/2016)... -- Perimeter Surveillance & Detection Systems, Biometrics ... Support & Other Service  The latest report ... analysis of the global Border Security market . ... $17.98 billion in 2016. Now: In November ... software and hardware technologies for advanced video surveillance. ...
Breaking Biology News(10 mins):